Your cart is empty.
By Joe Guterl
More than $72 billion – that is what some researchers estimate will be the global point-of-care (POC) biochemical diagnostic testing market size in 2027, up from $36 billion in 2021.1,2 The POC molecular diagnostics market is expected to reach $4-$5 billion in the same timeframe, up from about $3 billion in the 2020/2021 timeframe.2,3
The COVID-19 pandemic has dramatically changed the way we engage with healthcare, but other trends in disease, technology innovation, and healthcare infrastructure are also presenting new drivers and challenges to this tremendous growth. Point-of-care instrument providers that can offer more accurate, precise, flexible, and faster tools will be in the best position to leverage the drivers, mitigate the challenges, and capture POC market share.